AmerisourceBergen Corporation – Company Information

0

AmerisourceBergen Corporation is a multinational pharmaceutical services company, based in Chesterbrook, Pennsylvania, USA. It is publicly traded on the New York Stock Exchange (NYSE) under the stock ticker symbol ‘ABC’.

The company focuses on providing drug distribution services for pharmaceutical manufacturers and healthcare providers, designed to reduce costs and improve patient outcomes.

Approximately one fifth of pharmaceuticals sold and distributed in the US are handled by AmerisourceBergen.

It was formed in 2001 after the merger of Bergen Brunswig Corporation and AmeriSource Health Corporation.

Its pharmaceutical distribution business is operated under the following business units:

Drug Corporation: providing pharmaceuticals, staffing, pharmacy automation and professional consultation services.

Speciality Group: in oncology, plasma-derivative and biotech product distribution.

Consulting Services: partners with manufacturers to prove product value and expand market access.

World Courier: specialty logistics for global clinical trials delivering fully-integrated GxP-compliant temperature-controlled transport, distribution and storage solutions.

Overview

AmerisourceBergen Corporation logo


AmerisourceBergen Corporation Financial Results, Years Ended September 30

Operating data (in $ thousands) 2014 2013
Revenue $119,569,127 $87,959,167
Cost of goods sold $116,586,761 $85,451,348
Gross profit $2,982,366 $2,507,819
Distribution, selling and administrative expenses $1,587,261 $1,333,712
Depreciation $159,328 $135,047
Amortization $25,962 $27,139
Warrants $422,739 $90,055
Operating income $778,884 $898,399
Income from continuing operations $284,030 $493,435
Net income $276,484 $433,707
Balance sheet data (in $ thousands)
Total assets $21,532,183 $18,918,638
Long-term debt $1,995,632 $1,396,606
Total stockholders’ equity $1,956,899 $2,319,745
Common share data (in $)
Basic earnings per share $1.22 $1.88
Diluted earnings per share $1.17 $1.84
Cash flow data (in $ thousands)
Net cash provided by operating activities $1,463,153 $788,125
Net cash provided by (used for) investing activities $(384,155) $117,260
Net cash used for financing activities $(501,491) $(740,987)
Cash and cash equivalents at beginning of year $1,231,006 $1,006,608
Cash and cash equivalents at end of year $1,808,513 $1,231,006

Source: “AmerisourceBergen Corporation Form 10-K 2014”


You might also like More from author